氨甲环酸给药对急性自发性脑出血远隔脑缺血病灶的影响:一项随机临床试验的子研究
这项前瞻性嵌套MRI子研究基于多中心、双盲、安慰剂对照的3期TICH-2随机临床试验,纳入219例急性自发性脑出血患者,比较氨甲环酸与安慰剂在2周内远隔DWI高信号病灶的患病率和数量。结果显示两组患病率(20.8% vs 22.8%;OR 0.71;95%CI 0.33-1.53;P=0.39)和平均数量(1.75 vs 1.81;MD -0.08;95%CI -0.36至0.20;P=0.59)均无显著差异。
要点
- 氨甲环酸组与安慰剂组远隔DWI高信号病灶患病率无显著差异(20.8% vs 22.8%;OR 0.71;95%CI 0.33-1.53;P=0.39)。
- 两组平均DWI高信号病灶数量无显著差异(1.75 vs 1.81;MD -0.08;95%CI -0.36至0.20;P=0.59)。
- 探索性分析中,发病3小时内随机化或伴慢性梗死患者接受氨甲环酸后出现DWIHL的可能性似乎更低,而很可能脑淀粉样血管病患者似乎更高。
核心结论
- 这项随机临床试验子研究未发现急性脑出血后氨甲环酸治疗增加远隔DWI高信号病灶患病率或数量的证据。
- 这些发现为正在和未来的试验提供了 reassurance,即氨甲环酸治疗急性脑出血不太可能诱发脑缺血事件。
研究设计与样本
- TICH-2试验的前瞻性嵌套磁共振成像子研究,TICH-2为多中心、双盲、安慰剂对照的3期随机临床试验。
- 2015年7月1日至2017年9月30日招募,随访至随机化后90天,纳入同意额外MRI扫描或临床MRI数据符合子研究脑MRI方案的急性自发性脑出血患者。
- 共纳入219例有脑MRI数据的参与者(平均[SD]年龄65.1[13.8]岁;126例男性[57.5%]),其中96例(43.8%)随机分配至氨甲环酸组,123例(56.2%)分配至安慰剂组。
- 氨甲环酸组在脑出血发病8小时内给予1 g于100 mL静脉负荷剂量,随后1 g于250 mL输注;安慰剂组在发病8小时内给予0.9%氯化钠。
- 脑MRI包括DWI在2周内完成,数据分析于2020年1月20日按意向性治疗进行。
主要发现
- 氨甲环酸组与安慰剂组远隔DWIHL患病率无增加(20/96[20.8%] vs 28/123[22.8%];OR 0.71;95%CI 0.33-1.53;P=0.39)。
- 氨甲环酸组与安慰剂组平均(SD)DWIHL数量无增加(1.75[1.45] vs 1.81[1.71];MD -0.08;95%CI -0.36至0.20;P=0.59)。
- 探索性分析中,发病3小时内随机化或伴慢性梗死的参与者接受氨甲环酸后出现DWIHL的可能性似乎更低。
- 探索性分析中,很可能脑淀粉样血管病的参与者接受氨甲环酸后出现DWIHL的可能性似乎更高。
关键数值与推荐
- 远隔DWIHL患病率:氨甲环酸组20.8%(20/96) vs 安慰剂组22.8%(28/123);OR 0.71;95%CI 0.33-1.53;P=0.39。
- 平均(SD)DWIHL数量:氨甲环酸组1.75(1.45) vs 安慰剂组1.81(1.71);MD -0.08;95%CI -0.36至0.20;P=0.59。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hyperintense foci on diffusion-weighted imaging (DWI) that are spatially remote from the acute hematoma occur in 20% of people with acute spontaneous intracerebral hemorrhage (ICH). Tranexamic acid, a hemostatic agent that is under investigation for treating acute ICH, might increase DWI hyperintense lesions (DWIHLs). OBJECTIVE: To establish whether tranexamic acid compared with placebo increased the prevalence or number of remote cerebral DWIHLs within 2 weeks of ICH onset. DESIGN, SETTING, AND PARTICIPANTS: This prospective nested magnetic resonance imaging (MRI) substudy of a randomized clinical trial (RCT) recruited participants from the multicenter, double-blind, placebo-controlled, phase 3 RCT (Tranexamic Acid for Hyperacute Primary Intracerebral Hemorrhage [TICH-2]) from July 1, 2015, to September 30, 2017, and conducted follow-up to 90 days after participants were randomized to either the tranexamic acid or placebo group. Participants had acute spontaneous ICH and included TICH-2 participants who provided consent to undergo additional MRI scans for the MRI substudy and those who had clinical MRI data that were compatible with the brain MRI protocol of the substudy. Data analyses were performed on an intention-to-treat basis on January 20, 2020. INTERVENTIONS: The tranexamic acid group received 1 g in 100-mL intravenous bolus loading dose, followed by 1 g in 250-mL infusion within 8 hours of ICH onset. The placebo group received 0.9% saline within 8 hours of ICH onset. Brain MRI scans, including DWI, were performed within 2 weeks. MAIN OUTCOMES AND MEASURES: Prevalence and number of remote DWIHLs were compared between the treatment groups using binary logistic regression adjusted for baseline covariates. RESULTS: A total of 219 participants (mean [SD] age, 65.1 [13.8] years; 126 men [57.5%]) who had brain MRI data were included. Of these participants, 96 (43.8%) were randomized to receive tranexamic acid and 123 (56.2%) were randomized to receive placebo. No baseline differences in demographic characteristics and clinical or imaging features were found between the groups. There was no increase for the tranexamic acid group compared with the placebo group in DWIHL prevalence (20 of 96 [20.8%] vs 28 of 123 [22.8%]; odds ratio [OR], 0.71; 95% CI, 0.33-1.53; P = .39) or mean (SD) number of DWIHLs (1.75 [1.45] vs 1.81 [1.71]; mean difference [MD], -0.08; 95% CI, -0.36 to 0.20; P = .59). In an exploratory analysis, participants who were randomized within 3 hours of ICH onset or those with chronic infarcts appeared less likely to have DWIHLs if they received tranexamic acid. Participants with probable cerebral amyloid angiopathy appeared more likely to have DWIHLs if they received tranexamic acid. CONCLUSIONS AND RELEVANCE: This substudy of an RCT found no evidence of increased prevalence or number of remote DWIHLs after tranexamic acid treatment in acute ICH. These findings provide reassurance for ongoing and future trials that tranexamic acid for acute ICH is unlikely to induce cerebral ischemic events. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN93732214.
引用
- Pszczolkowski S, Sprigg N, Woodhouse LJ, et al. Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 35311937. doi:10.1001/jamaneurol.2022.0217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。